All In Biotech

Drug Trial Radar · NCT04227366

Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

An International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-089 (JSC BIOCAD, Russia) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: May 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

154

Actual

Start

Nov 19, 2019

Primary completion

Mar 15, 2021

Study completion Mar 1, 2022

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Jan 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BCD-089 is the original therapeutic monoclonal antibody binding the alpha subunit of the IL-6 receptor. The aim of the study is to demonstrate the efficacy and safety of BCD-089 in combination with methotrexate in patients with active rheumatoid arthritis resistant to monotherapy with methotrexate.

Conditions

  • Rheumatoid Arthritis

Interventions

  • BCD-089Biological

    BCD-089 162 mg SC

  • PlaceboBiological

    Placebo

  • MethotrexatDrug

    15 to 25 mg/week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ACR 20 responseTime frame: Week 12
  2. Low disease activityTime frame: Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Institute of Rheumotology

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.